During the past decade, Instituto Nacional del Cáncer conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 10 clinical trials were completed, i.e. on average, 142.9% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 4 clinical trials were completed. i.e. 200% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Instituto Nacional del Cáncer" #1 sponsor was "Hoffmann-La Roche" with 5 trials, followed by "Pfizer" with 2 trials sponsored, "Agennix" with 1 trials sponsored, "Bayer" with 1 trials sponsored and "Breast Cancer Trials, Australia and New Zealand" with 1 trials sponsored. Other sponsors include 4 different institutions and companies that sponsored additional 14 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Instituto Nacional del Cáncer" #1 collaborator was "Breast International Group" with 3 trials as a collaborator, "ETOP IBCSG Partners Foundation" with 2 trials as a collaborator, "Astellas Pharma Inc" with 1 trials as a collaborator, "European Organisation for Research and Treatment of Cancer - EORTC" with 1 trials as a collaborator and "Johnson & Johnson Pharmaceutical Research & Development, L.L.C." with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.

According to Clinical.Site data, the most researched conditions in "Instituto Nacional del Cáncer" are "Breast Cancer" (3 trials), "Breast Neoplasms" (1 trials), "Castration-Resistant Prostate Cancer" (1 trials), "Cognitive Dysfunction" (1 trials) and "Colorectal Cancer" (1 trials). Many other conditions were trialed in "Instituto Nacional del Cáncer" in a lesser frequency.

Most popular intervention types in "Instituto Nacional del Cáncer" are "Drug" (16 trials), "Device" (2 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "Cyclophosphamide" (2 trials), "Herceptin" (2 trials), "5-fluorouracil" (1 trials) and "Ado-trastuzumab emtamsine" (1 trials). Other intervention names were less common.

The vast majority of trials in "Instituto Nacional del Cáncer" are 15 trials for "All" genders, 3 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Instituto Nacional del Cáncer". undefined are not yet recruiting, 2 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 15 completed trials in Instituto Nacional del Cáncer, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Instituto Nacional del Cáncer, 1 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 11 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".